226-240 of 831
Managing MS-Related Fatigue with Therapeutic, Lifestyle, and Behavioral Interventions
On the Frontlines of Multiple SclerosisManaging MS-Related Fatigue with Therapeutic, Lifestyle, and Behavioral Interventions
Glenn Wylie, DPhil
Gaps in Schizophrenia Spectrum Disorders Care: A Look at Causes and Solutions
NeuroFrontiersGaps in Schizophrenia Spectrum Disorders Care: A Look at Causes and Solutions
Natalie Bareis, PhD, LMSW
Fatigue in Multiple Sclerosis: Investigating Longitudinal Determinants
NeuroFrontiersFatigue in Multiple Sclerosis: Investigating Longitudinal Determinants
Developments in Duchenne Muscular Dystrophy Care: Examining the Options
NeuroFrontiersDevelopments in Duchenne Muscular Dystrophy Care: Examining the Options
Caring for Women with MS: Key Considerations for Pregnancy and Menopause
NeuroFrontiersCaring for Women with MS: Key Considerations for Pregnancy and Menopause
Schizophrenia Care: Managing Symptoms with Muscarinic Receptor Agonists
On the Frontlines of SchizophreniaSchizophrenia Care: Managing Symptoms with Muscarinic Receptor Agonists
Steven Paul, MD
- advertisement
Differentiating gMG for Diagnostic Precision: The Role of Fatigable Weakness
NeuroFrontiersDifferentiating gMG for Diagnostic Precision: The Role of Fatigable Weakness
Maxwell H. Levy, MD
Developments in Schizophrenia Care: An Alternative to Dopamine Receptor Blockage
NeuroFrontiersDevelopments in Schizophrenia Care: An Alternative to Dopamine Receptor Blockage
Steven Paul, MD
Navigating Myasthenia Gravis in Adolescents and Young Adults
NeuroFrontiersNavigating Myasthenia Gravis in Adolescents and Young Adults
Jonathan Strober, MD
Quality of Life in Schizophrenia Patients: Challenges and Practical Approaches to Care
On the Frontlines of SchizophreniaQuality of Life in Schizophrenia Patients: Challenges and Practical Approaches to Care
Desiree Matthews, PMHNP-BC
Spotting the Signs: Early Identification and Management of Schizophrenia
On the Frontlines of SchizophreniaSpotting the Signs: Early Identification and Management of Schizophrenia
Desiree Matthews, PMHNP-BC
Silent Brain Damage in ATTR-CM: Exploring Neurological Impacts
Spotlight On ATTR-CMSilent Brain Damage in ATTR-CM: Exploring Neurological Impacts
- advertisement
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
NeuroFrontiersRozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
Gil I. Wolfe MD, FAAN
Challenges in DMD: Understanding the Height Factor
NeuroFrontiersChallenges in DMD: Understanding the Height Factor
Schizophrenia Care: Improving Social Cognition and Motivation
On the Frontlines of SchizophreniaSchizophrenia Care: Improving Social Cognition and Motivation
Michael Green, PhD
